Skip to main content

Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia

Abstract

The effects of hyperprolactinemia on metabolic parameters are not clear and a few data evaluating adiponectin levels in prolactinoma and idiopathic hyperprolactinemia exist. The aim of this study was to evaluate the effects of hyperprolactinemia on body weight, insulin resistance, beta cell function, and leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma glucose, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels. Plasma insulin levels and HOMA indexes (both insulin resistance and beta indexes) were significantly higher in hyperprolactinemic women. The other parameters were similar between both groups. There was a positive correlation between prolactin levels and fasting plasma glucose in hyperprolactinemic women. The results of this study showed that high prolactin levels may be associated with hyperinsulinemia and insulin resistance in premenopausal women. This effect seems to be independent of body weight, leptin and adiponectin levels. High prolactin levels may directly stimulate insulin secretion from pancreas and directly cause hepatic and whole-body insulin resistance.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009)

    PubMed  Article  CAS  Google Scholar 

  2. F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A.H. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)

    Article  Google Scholar 

  3. T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008)

    PubMed  Article  CAS  Google Scholar 

  4. G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299–306 (2011)

    PubMed  Article  CAS  Google Scholar 

  5. G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)

    PubMed  Article  CAS  Google Scholar 

  6. C. Schmid, D.L. Goede, R.S. Hauser, M. Brandle, Increased prevalence of high body mass index in patients presenting with pituitary tumors: severe obesity in patients with macroprolactinoma. Swiss Med. Wkly. 136, 254–258 (2006)

    PubMed  Google Scholar 

  7. Y. Greenman, K. Tordjman, N. Stern, Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin. Endocrinol. 48, 547–553 (1998)

    Article  CAS  Google Scholar 

  8. M. Doknic, S. Pekic, M. Zarkovic, M. Medic-Stojanoska, C. Dieguez, F. Casanueva, V. Popovic, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol. 147, 77–84 (2002)

    PubMed  Article  CAS  Google Scholar 

  9. G.J. Wang, N.D. Volkow, J. Logan, N.R. Pappas, C.T. Wong, W. Zhu, N. Netusil, J.S. Fowler, Brain dopamine and obesity. Lancet 357, 354–357 (2001)

    PubMed  Article  CAS  Google Scholar 

  10. E.R. Hugo, T.D. Brandegourg, C.E.S. Comstock, K.S. Gersin, J.J. Susman, N. Ben-Jonathan, LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147, 306–313 (2006)

    PubMed  Article  CAS  Google Scholar 

  11. C. Ling, L. Svensson, B. Odén, B. Weijdegård, B. Edén, S. Edén, H. Billig, Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J. Clin. Endocrinol. Metab. 88, 1804–1808 (2003)

    PubMed  Article  CAS  Google Scholar 

  12. T.J. Highman, J.E. Friedman, L.P. Huston, W.W. Wong, P.M. Catalano, Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am. J. Obstet. Gynecol. 178, 1010–1015 (1998)

    PubMed  Article  CAS  Google Scholar 

  13. N.F. Butte, J.M. Hopkinson, M.A. Nicolson, Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J. Clin. Endocrinol. Metab. 82, 585–589 (1997)

    PubMed  Article  CAS  Google Scholar 

  14. H. Balci, K. Akgun-Dar, N. Gazioglu, A. Kapucu, M. Bolayirli, B. Oz, The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. Pituitary 12, 170–176 (2009)

    PubMed  Article  CAS  Google Scholar 

  15. R. Landgraf, M.M. Landgraf-Leurs, A. Weissmann, R. Hörl, K. von Werder, P.C. Scriba, Prolactin: a diabetogenic hormone. Diabetologia 13, 99–104 (1977)

    PubMed  Article  CAS  Google Scholar 

  16. G. Schernthaner, R. Prager, C. Punzengruber, A. Luger, Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28, 138–142 (1985)

    PubMed  CAS  Google Scholar 

  17. A. Tuzcu, M. Bahceci, M. Dursun, C. Turgut, S. Bahceci, Insulin sensitivity and hyperprolactinemia. J. Endocrinol. Invest. 26, 341–346 (2003)

    PubMed  CAS  Google Scholar 

  18. O. Serri, L. Ling, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. 64, 366–370 (2006)

    CAS  Google Scholar 

  19. S.S. Inancli, A. Usluogullari, Y. Ustu, S. Caner, A.A. Tam, R. Ersoy, B. Cakir, Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine (2012). doi:10.1007/s12020-012-9857-y

    PubMed  Google Scholar 

  20. L. Nilsson, R. Binart, M. Bohlooly-Y, M. Bramnert, E. Egecioglu, J. Kindblom, P.A. Kelly, J.J. Kopchick, C.J. Ormandy, C. Ling, H. Billig, Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem. Biophys. Res. Commun. 331, 1120–1126 (2005)

    PubMed  Article  CAS  Google Scholar 

  21. J. Fuglsang, C. Skjærbæk, J. Frystyk, A. Flyvbjerg, P. Ovesen, A longitudinal study of serum adiponectin during normal pregnancy. BJOG 113, 110–113 (2006)

    PubMed  Article  CAS  Google Scholar 

  22. M. Asai-Sato, M. Okamoto, M. Endo, H. Yoshida, M. Murase, M. Ikeda, H. Sakakibara, T. Takahashi, F. Hirahara, Hypoadiponectinemia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr. J. 53, 555–652 (2006)

    PubMed  Article  CAS  Google Scholar 

  23. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19–25 (2004)

    Google Scholar 

  24. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Androgen Excess Society: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)

    PubMed  Article  CAS  Google Scholar 

  25. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)

    PubMed  Article  CAS  Google Scholar 

  26. L.B. Creemers, P.M.J. Zelissen, J.W. van’t Verlaat, H.P.F. Koppeschaar, Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 125, 392–396 (1991)

    PubMed  CAS  Google Scholar 

  27. K. Berinder, T. Nyström, C. Höybye, K. Hall, A.-L. Hulting, Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14, 199–207 (2011)

    PubMed  Article  CAS  Google Scholar 

  28. R. Yermus, S. Ezzat, Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin. Endocrinol. 56, 562 (2002)

    Article  CAS  Google Scholar 

  29. H. Soran, J. Wilding, I. MacFarlane, Body weight and prolactinoma: a retrospective study. Int. J. Obes. Relat. Metab. Disord. 28, 183 (2004)

    PubMed  Article  CAS  Google Scholar 

  30. R. Mukherjea, T.W. Castonguay, L.W. Douglass, P. Moser-Veillon, Elevated leptin concentrations in pregnancy and lactation: possible role as a modulator of substrate utilization. Life Sci. 65, 1183–1193 (1999)

    PubMed  Article  CAS  Google Scholar 

  31. H. Pijl, S. Ohashi, M. Matsuda, Y. Miyazaki, A. Mahankali, V. Kumar, R. Pipek, P. Iozzo, J.L. Lancaster, A.H. Cincotta, R.A. DeFronzo, Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23, 1154–1161 (2000)

    PubMed  Article  CAS  Google Scholar 

  32. P. Kleiblova, D. Springer, M. Haluzik, The influence of hormonal changes during menstrual cycle on serum adiponectin concentrations in healthy women. Physiol. Res. 55, 661–666 (2006)

    PubMed  CAS  Google Scholar 

  33. S.S. Tworoger, C. Mantzoros, S.E. Hankinson, Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels. Obesity 15, 2217–2224 (2007)

    PubMed  Article  CAS  Google Scholar 

  34. L.F. De Assuncao Alves Rodrigues, S.M. Campos, P.A. Miranda, M.F. Bizzi, P.H. Sales do Amaral, A.V. Giannetti, A. Ribeiro-Oliveira, Prolactinoma: a condition associated with hypoadiponectinemia. Horm. Metab. Res. 44, 832–838 (2012)

    Google Scholar 

  35. P. Cejkova, M. Fojtiova, M. Cerna, Immunomodulatory role of prolactin in diabetes development. Autoimmun. Rev. 9, 23–27 (2009)

    PubMed  Article  CAS  Google Scholar 

  36. S. Park, D.S. Kim, J.W. Daily, S.-H. Kim, Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats. Diabetes Metab. Res. Rev. 27, 564–574 (2011)

    PubMed  Article  CAS  Google Scholar 

  37. T. Brandebourg, E. Hugo, N. Ben-Jonathan, Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes. Metab. 9, 464–476 (2007)

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Novartis Pharmaceuticals and Turkish Neuroendocrine Association for providing the assays for the study and Prof. Dr. Yuksel Bek for assisting in statistical analyses.

Ethical standards

The study was approved by the Ethics Committee of Ondokuz Mayis University School and the study complies with the current laws of our country.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aysegul Atmaca.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Atmaca, A., Bilgici, B., Ecemis, G.C. et al. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine 44, 756–761 (2013). https://doi.org/10.1007/s12020-013-9931-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-9931-0

Keywords

  • Hyperprolactinemia
  • Prolactinoma
  • Body weight
  • Insulin resistance
  • Leptin
  • Adiponectin